Mary Rinella to Liver
This is a "connection" page, showing publications Mary Rinella has written about Liver.
Connection Strength
2.773
-
Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
Score: 0.364
-
Pioneering the path to NASH biomarker approval. Nat Med. 2023 10; 29(10):2416-2417.
Score: 0.162
-
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024 Mar 01; 79(3):674-689.
Score: 0.161
-
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 05 01; 77(5):1797-1835.
Score: 0.156
-
Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers. Clin Liver Dis. 2023 05; 27(2):251-273.
Score: 0.155
-
Liver biopsy in living donors. Liver Transpl. 2002 Dec; 8(12):1123-5.
Score: 0.153
-
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 03; 76(3):536-548.
Score: 0.142
-
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517.
Score: 0.142
-
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
Score: 0.139
-
NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021 05; 73(5):2028-2038.
Score: 0.137
-
The times they are a-changin' (for NAFLD as well). J Hepatol. 2020 12; 73(6):1307-1309.
Score: 0.131
-
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol. 2019 04; 70(4):735-744.
Score: 0.116
-
Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int. 2018 04; 38(4):706-714.
Score: 0.107
-
Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol. 2017 05; 112(5):752-754.
Score: 0.104
-
Moderate Exercise for Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 2016 08 01; 176(8):1083-4.
Score: 0.098
-
Liraglutide-induced autoimmune hepatitis. JAMA Intern Med. 2014 Jun; 174(6):984-7.
Score: 0.085
-
Hepatic overexpression of abcb11 promotes hypercholesterolemia and obesity in mice. Gastroenterology. 2011 Oct; 141(4):1404-11, 1411.e1-2.
Score: 0.069
-
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011 Jul-Sep; 10(3):277-86.
Score: 0.069
-
Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008 May; 49(5):1068-76.
Score: 0.055
-
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
Score: 0.041
-
Editorial: global liver fat accumulation and global health-towards a sustainable development goal. Authors' reply. Aliment Pharmacol Ther. 2022 02; 55(4):489-490.
Score: 0.036
-
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol. 2022 05; 76(5):1030-1041.
Score: 0.036
-
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020 08; 52(3):513-526.
Score: 0.032
-
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2020 04; 158(5):1334-1345.e5.
Score: 0.031
-
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 07; 68(1):349-360.
Score: 0.028
-
Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015 12 17; 1:15080.
Score: 0.024